Your browser version may not work well with NCBI's Web applications. More information here...
1: Lancet. 1995 Feb 18;345(8947):423-4.Links
Comment in:
Lancet. 1995 Apr 15;345(8955):990.
Lancet. 1995 Apr 15;345(8955):990-1.
Lancet. 1995 May 13;345(8959):1238-9.
Lancet. 1995 May 13;345(8959):1238; author reply 1239.

Vitamin-D-receptor-gene polymorphisms and change in lumbar-spine bone mineral density.

Ferrari S, Rizzoli R, Chevalley T, Slosman D, Eisman JA, Bonjour JP.

WHO Collaborating Centre for Osteoporosis and Bone Disease, Department of Medicine, Geneva, Switzerland.

Common vitamin-D-receptor (VDR) gene allelic variants predict bone mineral density. We analysed VDR alleles and rate of change of lumbar-spine bone mineral density over 18 months in 72 elderly subjects. 9 BB homozygotes lost bone mineral density but 26 homozygotes for the alternative genotype (bb) did not (mean change -2.3 [SE 1.0] vs 0.9 [0.7]% per year, p < 0.05), irrespective of calcium intake. Among 37 heterozygotes (Bb), however, change in bone mineral density correlated with calcium intake (r = 0.35, p < 0.03). This association between a genetic marker and rate of bone loss in the elderly suggests that the effect of calcium intake on maintenance of bone mass could relate to VDR gene polymorphisms.

PMID: 7853953 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Calcitriol (Rocaltrol® )

    Calcitriol is a form of vitamin D that is used to treat and prevent low levels of calcium in the blood of patients whose kidneys or parathyroid glands (glands in the neck that release natural substances to control the am...

  • Source: AHFS Consumer Medication Information